These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 23246016

  • 1. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK.
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [Abstract] [Full Text] [Related]

  • 2. [Value of dual-energy CT-based volumetric iodine-uptake in the evaluation of chemotherapy efficacy in advanced gastric cancer].
    Chen LF, Fu GZ, Huang DP, Man Y, Jin Y, Dong QT, Huang YB, Chen YC, Wang HQ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Oct 25; 22(10):977-983. PubMed ID: 31630497
    [Abstract] [Full Text] [Related]

  • 3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan 25; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 4. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
    Bargellini I, Crocetti L, Turini FM, Lorenzoni G, Boni G, Traino AC, Caramella D, Cioni R.
    Cardiovasc Intervent Radiol; 2018 Sep 25; 41(9):1373-1383. PubMed ID: 29654507
    [Abstract] [Full Text] [Related]

  • 5. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 25; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y.
    World J Gastroenterol; 2012 Oct 28; 18(40):5753-8. PubMed ID: 23155317
    [Abstract] [Full Text] [Related]

  • 7. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V.
    Eur J Radiol; 2013 May 28; 82(5):e205-11. PubMed ID: 23273822
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M.
    Acta Radiol; 2018 Jul 28; 59(7):765-772. PubMed ID: 28927298
    [Abstract] [Full Text] [Related]

  • 9. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 10. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 01; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 11. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Sacco R, Faggioni L, Bargellini I, Ginanni B, Battaglia V, Romano A, Bertini M, Bresci G, Bartolozzi C.
    Dig Liver Dis; 2013 Sep 01; 45(9):776-81. PubMed ID: 23578581
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H, Malagari K, Gkoutzios P, Kalokairinou M, Stamatiou K, Chatzimichail K, Kornezos I, Karagiannis E, Kiltenis M, Papadaki MG.
    Med Ultrason; 2012 Jun 01; 14(2):87-94. PubMed ID: 22675707
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr 01; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 16. Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
    Mulé S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C.
    Radiology; 2018 Aug 01; 288(2):445-455. PubMed ID: 29584597
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Ishikawa T, Nakano I, Goto H, Hirooka Y.
    Oncology; 2016 Aug 01; 91(5):261-266. PubMed ID: 27622905
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.